{
    "id": 20922,
    "fullName": "MAP2K1 Y134C",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K1 Y134C lies within the protein kinase domain of the Map2k1 protein (UniProt.org). Y134C has been identified in the scientific literature (PMID: 18186519) but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 7939,
                    "pubMedId": 18186519,
                    "title": "Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18186519"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5604,
        "geneSymbol": "MAP2K1",
        "terms": [
            "MAP2K1",
            "CFC3",
            "MAPKK1",
            "MEK1",
            "MKK1",
            "PRKMK1"
        ]
    },
    "variant": "Y134C",
    "createDate": "04/11/2016",
    "updateDate": "02/19/2020",
    "referenceTranscriptCoordinates": {
        "id": 173546,
        "transcript": "NM_002755",
        "gDna": "chr15:g.66436855A>G",
        "cDna": "c.401A>G",
        "protein": "p.Y134C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6448,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713).",
            "molecularProfile": {
                "id": 23451,
                "profileName": "KRAS Q61H MAP2K1 Y134C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6449,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713).",
            "molecularProfile": {
                "id": 23451,
                "profileName": "KRAS Q61H MAP2K1 Y134C"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21428,
            "profileName": "MAP2K1 Y134C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23451,
            "profileName": "KRAS Q61H MAP2K1 Y134C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 173546,
            "transcript": "NM_002755",
            "gDna": "chr15:g.66436855A>G",
            "cDna": "c.401A>G",
            "protein": "p.Y134C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 173547,
            "transcript": "XM_017022411",
            "gDna": "chr15:g.66436855A>G",
            "cDna": "c.401A>G",
            "protein": "p.Y134C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}